Retraction: TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types
Retraction to: Transl Cancer Res 2019;8:1423-37.
The editorial office was alerted by the Uniformed Services University that the paper entitled “TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types” (1) published in the Vol 8, No 4 (August 31, 2019) issue of Translational Cancer Research contained several falsified or inappropriately duplicated images according to an internal research misconduct investigation.
The authors were contacted about these integrity concerns and all authors except for the corresponding author agreed with the retraction. The corresponding author did not reply. The editorial office decided to retract this paper in accordance with the journal’s retraction policy.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Paucarmayta A, Taitz H, Casablanca Y, et al. TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types. Transl Cancer Res 2019;8:1423-37. [Crossref] [PubMed]
